

GLAXOSMITHKLINE PLC
Form 6-K
May 05, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending May 2011

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc - Result of AGM

GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting today, all resolutions, including those electing and re-electing Board members, were passed by shareholders.

GlaxoSmithKline Annual General Meeting Poll Results

The following table shows the votes cast for each resolution:

| | Resolution | Total votes for* | % | Total votes against | % | Total votes cast | Votes withheld** |
|----|---|---------------------|-------|------------------------|------|---------------------|---------------------|
| 1 | Adoption of Financial Statements | 3,849,724,841 | 99.90 | 3,972,004 | 0.10 | 3,853,696,845 | 4,824,826 |
| 2 | Approval of the Remuneration Report | 3,506,794,850 | 92.88 | 268,917,463 | 7.12 | 3,775,712,313 | 82,829,542 |
| 3 | Election of Simon Dingemans | 3,848,384,170 | 99.88 | 4,592,054 | 0.12 | 3,852,976,224 | 5,550,786 |
| 4 | Election of Ms Stacey Cartwright | 3,841,823,906 | 99.71 | 11,062,363 | 0.29 | 3,852,886,269 | 5,643,742 |
| 5 | Election of Ms Judy Lewent | 3,843,559,263 | 99.75 | 9,499,395 | 0.25 | 3,853,058,658 | 5,471,278 |
| 6 | Re-election of Sir Christopher Gent | 3,736,569,130 | 96.97 | 116,649,598 | 3.03 | 3,853,218,728 | 5,314,008 |
| 7 | Re-election of Andrew Witty | 3,848,715,490 | 99.88 | 4,521,805 | 0.12 | 3,853,237,295 | 5,293,227 |
| 8 | Re-election of Professor Sir Roy Anderson | 3,849,621,453 | 99.91 | 3,645,550 | 0.09 | 3,853,267,003 | 5,262,933 |
| 9 | Re-election of Dr Stephanie Burns | 3,845,994,787 | 99.81 | 7,252,653 | 0.19 | 3,853,247,440 | 5,282,496 |
| 10 | Re-election of Larry Culp | 3,679,273,731 | 95.49 | 173,856,451 | 4.51 | 3,853,130,182 | 5,398,951 |
| 11 | Re-election of Sir Crispin Davis | 3,845,288,843 | 99.80 | 7,870,747 | 0.20 | 3,853,159,590 | 5,370,346 |
| 12 | Re-election of Sir Deryck Maughan | 3,618,533,477 | 93.91 | 234,597,016 | 6.09 | 3,853,130,493 | 5,409,443 |
| 13 | Re-election of James Murdoch | 3,749,042,808 | 97.30 | 103,982,301 | 2.70 | 3,853,025,109 | 5,504,826 |
| 14 | Re-election of Dr Daniel | 3,849,525,259 | 99.91 | 3,602,607 | 0.09 | 3,853,127,866 | 5,402,070 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | |
|----|--|---------------|-------|-------------|------|---------------|------------|
| 15 | Podolsky Re-election of Dr Moncef Slaoui | 3,848,000,866 | 99.87 | 5,004,470 | 0.13 | 3,853,005,336 | 5,225,725 |
| 16 | Re-election of Tom de Swaan | 3,767,791,974 | 97.78 | 85,429,903 | 2.22 | 3,853,221,877 | 5,318,058 |
| 17 | Re-election of Sir Robert Wilson | 3,849,258,200 | 99.90 | 4,000,688 | 0.10 | 3,853,258,888 | 5,270,983 |
| 18 | Re-appointment of Auditors | 3,772,864,832 | 99.32 | 25,647,503 | 0.68 | 3,798,512,335 | 60,025,660 |
| 19 | Remuneration of Auditors | 3,819,410,091 | 99.67 | 12,638,825 | 0.33 | 3,832,048,916 | 26,477,992 |
| 20 | To authorise the company to make donations to political organisations and incur political expenditure | 3,758,221,639 | 97.62 | 91,644,592 | 2.38 | 3,849,866,231 | 8,636,488 |
| 21 | Authority to allot shares | 3,781,033,581 | 98.16 | 70,843,798 | 1.84 | 3,851,877,379 | 6,624,572 |
| 22 | Disapplication of pre-emption rights*** | 3,811,196,075 | 99.00 | 38,468,694 | 1.00 | 3,849,664,769 | 8,832,253 |
| 23 | Authority for the Company to purchase its own shares*** | 3,786,160,872 | 98.25 | 67,324,020 | 1.75 | 3,853,484,892 | 5,049,760 |
| 24 | Exemption from statement of senior statutory auditor's name | 3,829,887,610 | 99.49 | 19,439,945 | 0.51 | 3,849,327,555 | 9,159,773 |
| 25 | Reduced notice of a general meeting other than an AGM*** | 3,549,744,749 | 92.16 | 301,776,965 | 7.84 | 3,851,521,714 | 7,016,010 |

Notes:

* Includes discretionary votes.

** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

*** Indicates Special Resolutions requiring a 75% majority.

The following table provides further relevant information:

| | GlaxoSmithKline's Eleventh AGM (2011) | GlaxoSmithKline's Tenth AGM (2010) |
|---|---|--|
| Issued share capital (excluding Treasury Shares) | 5,163,907,153 | 5,192,489,588 |
| Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) | 74.72% | 70.24% |
| Total shareholder population | 155,990 | 164,450 |
| Total number of proxies lodged | 9,886 | 11,148 |
| % of shareholders who lodged proxies | 6.34% | 6.78% |
| Number of shareholders, corporate representatives and proxies who attended the AGM | 364 | 325 |

V A Whyte
Company Secretary
5 May 2011

These results will shortly be available on the Company's website www.gsk.com.

Enquiries:

GlaxoSmithKline Enquiries:

| | | |
|---------------------|----------------|-----------------|
| UK Media enquiries: | David Mawdsley | (020) 8047 5502 |
| | Claire Brough | (020) 8047 5502 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Stephen Rea (020) 8047 5502
Alexandra Harrison (020) 8047 5502
David Daley (020) 8047 5502

US Media enquiries: Nancy Pekarek (919) 483 2839
Mary Anne Rhyne (919) 483 2839
Kevin Colgan (919) 483 2839
Jennifer Armstrong (919) 483 2839

European Analyst/Investor enquiries: Sally Ferguson (020) 8047 5543
Gary Davies (020) 8047 5503
Ziba Shamsi (020) 8047 3289

US Analyst/ Investor enquiries: Tom Curry (215) 751 5419
Jeff McLaughlin (215) 751 4890

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: May 5, 2011

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc